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ABSTRACT 
 
 
 
 
Systemic Lupus Erythematosus (SLE) is an autoimmune disorder that can affect every 
tissue in the body. Single nucleotide polymorphisms (SNPs) in the IRF5 and TNPO3 
genes are statistically associated with the development of SLE. My research identified 
correlations between IRF5/TNPO3 SNPs and specific lupus symptoms. Logistic 
regression analyses were conducted using 101 genetic variants in the IRF5/TNPO3 region 
that were genotyped in over 6,000 lupus patients of different ethnicities, with admixture 
covariates applied. Three clinical phenotypes displayed significant correlation (p < 
1.6x10
-5
) in subjects of European ancestry. For each of these phenotypes, a step-wise 
conditional analysis was conducted using two lupus associated single nucleotide 
polymorphisms (SNPs) at this genetic loci.  In Europeans, lupus disease onset (p-
valueEU=2.44x10
-16
, OR=0.67*) and the presence of anti-Ro (p-valueEU=2.09x10
-7
, 
OR=0.67) and anti-dsDNA (p-valueEU=4.15x10
-7
, OR=0.75) antibodies were associated 
with SNPs in the IRF5/TNPO3 genes. SNPs in the IRF5 promoter and those spanning 
IRF5 and TNPO3 were both associated with disease onset. The presence of anti-Ro and 
anti-dsDNA antibodies is only associated with SNPs in the IRF5 promoter. Genetic 
variants at the IRF5/TNPO3 locus are associated with lupus disease onset and production 
of anti-dsDNA and anti-Ro antibodies in lupus patients. SNPs in the promoter region of 
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IRF5 (associated with rs4728142) and SNPs spanning the IRF5 and TNPO3 genes 
(associated with rs12534421) contribute independently to these symptoms. 
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CHAPTER 1 
 
 
PREFACE 
 
 
 During the summer of 2012, I was selected to be one of 120 students involved in a 
Summer Undergraduate Research Fellowship at Cincinnati Children’s Hospital. It was a 
ten week, paid internship where students conducted research in the extensive research 
facilities of the third best children’s hospital in the nation.   Students in this program were 
placed in laboratories addressing almost every health issue available, from cancer to 
development to x-ray imaging and cardiac diseases. Because of my prior experience in 
bioinformatics analysis, I was chosen to analyze the genetic data of lupus patients in the 
rheumatology department.  
 Systemic Lupus Erythematosus (SLE or lupus) is a systemic autoimmune disorder 
that can affect every tissue in the human body. The body’s immune system is designed to 
differentiate between self (cells of the body) and non-self (cells from the outside world, 
which could possibly be harmful). When functioning correctly, immune cells attack non-
self cells while ignoring self cells. However, in an autoimmune disease like SLE, the 
immune system begins attacking the cells of the body.  
 Lupus is a heterogenous disease that can look very different in different people. 
There is no laboratory test for lupus, instead, there are eleven criteria that lead to a 
clinical diagnosis of lupus. Any four of the eleven must be manifested for a lupus 
diagnosis according to the American College of Rheumatology. They are: hematologic 
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Figure 1. A chart of the thirty phenotypic characteristics of SLE. The bold items are the eleven main 
criteria defined by the American Rheumatology. In addition to these thirty characteristics, the age of 
onset of lupus symptoms was also studied.  
SLE criteria 
Hematologic 
Disorders 
Lymphopenia 
Hemolytic Anemia 
Leucopenia 
Thrombocytopenia 
Discoid Rash 
Serositis 
Pleuritis 
Pericarditis 
Renal Disorders 
proteinuria 
cellular cast 
Malar rash 
neurologic 
disorders 
seizure 
psychosis 
Oral ulcer 
Immunologic 
disorders 
LE cell 
Lupus 
anticoagulant 
false positive 
VDRL 
Antinuclear 
antibodies 
Anti-dsDNA 
Anti-ro 
Anti-p 
Anti-sm 
Anti-la 
Anti-nrnp 
Arthritis 
Photosensitivity 
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(blood) disorders (anemia, leukopenia, lymphopenia, or thrombocytopenia), discoid rash, 
malar rash, serositis (inflammation of the lining around the lungs or heart), 
photosensitivity, renal (kidney) disorders, arthritis, neurologic disorders, oral ulcers, 
immunologic disorders (presence of certain autoantibodies, and abnormal antinuclear 
antibodies. These 11 symptoms have been broken into 30 subgroups, for which clinical 
data can be collected in lupus cases and controls (Figure 1). To study the genetic 
determinates of these sub-phenotypes, we used data from the Large Lupus Association 
Study 2 (LLAS2). Twenty-four different investigators contributed samples of DNA in 
addition to clinical information. Altogether, the LLAS2 dataset contained genetic and 
phenotypic data of over 6,000 people with lupus collected by researchers around the 
globe. Data from subjects of four different ancestral origins was studied: European 
American, Hispanic, African American, and Asian American (Figure 2). For each 
ancestry, covariates were calculated to account for admixture. Admixture is the concept 
Figure 2. Percentage of cases of different ethnicities analyzed from the LLAS2 data set.   
European 
49% 
African-American 
19% 
Hispanic 
16% 
Asian 
16% 
SLE Case Ethnicities 
European African-American Hispanic Asian
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that individuals are rarely ever purely one race, but instead have a genetic history from 
multiple ancestries. The covariates determine and account for mixed genetics in each 
individual in the study.  
Single Nucleotide Polymorphisms (SNPs) are variations in the genome that occur 
at a single base pair. These genetic variants are manifested in at least 5% of the 
population. The variations can be silent, causing no change in the gene’s protein 
structure, or they can change the promoter region, causing the gene to be over or under 
expressed, or the amino acid sequence, impacting the entire function of the resulting 
protein.  
There is no clearly defined single cause of lupus onset, rather, it is a result of both 
environmental and genetic causes. SNPs in over 45 genes have been repeatedly 
associated with lupus development, or etiology. Two of the most commonly associated 
loci includes the Interferon Regulatory Factor 5 (IRF5) gene and the nearby Transportin 3 
(TNPO3) gene. The IRF5 gene is especially noteworthy because it regulates chemicals 
called interferons. Interferons act as signals in the body that activate the immune response 
to viral infections. In lupus, interferons have been demonstrated to drive the autoimmune 
response and the pathology of SLE. In the LLAS2 study subjects, 101 genetic variants 
were genotyped in the IRF5/TNPO3 gene region. Case-control analysis of these SNPs 
showed significant association with lupus development. In fact, the group at the 
Cincinnati Children’s Hospital established that there are SNPs that are highly associated 
with lupus development in the promoter of IRF5 and in a region spanning the IRF5 and 
TNPO3 genes (p-value of less than 10
-8
).  
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 SNPs in a certain area tend to be found together, an occurrence known as linkage 
disequilibrium (LD). In the case of lupus development, the most associated SNPs are 
located in the promoter region of IRF5, and were closely linked with each other (Figure 
3). When the association of the SNP with the lowest p-value (rs4728142, located in the 
promoter of IRF5) was accounted for in a conditional analysis, the only remaining 
genetic association was found in a group of SNPs that span the IRF5 and TNPO3 genes. 
Upon further conditional analysis, removing the association of the next-most associated 
SNP (rs12534421) caused all association to be eliminated. This suggested that all 
significant association with lupus development was linked with two main SNPs in the 
IRF5/TNPO3 area.  
 Although studies have shown the association of SNPs in the IRF5 locus with 
lupus development, there has been little analysis of the possible association with specific 
symptoms in lupus. My research sought to identify correlations between SNPs and the 
development of lupus sub-phenotypes. I used the statistical software package PLINK 
version 1.07 to analyze the LLAS2 data. PLINK is designed to perform in-depth analyses 
of SNP associations, and it enabled me to conduct a sub-phenotypic logistic regression 
analysis (see Chapter 3) of SNPs in the IRF5/TNPO3 region, identifying connections 
Figure 3. SNP locations in reference to the IRF5 and TNPO3 genes. The black bars show the gene 
locations, and the two gray boxes are two groups of SNPs that are in high linkage within the gray 
region, but display little association with the other SNP group. The relative locations of SNPs 
connected to SLE symptoms are shown.  
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between displayed lupus symptoms and the SNPs present in this gene area. After 
formatting the data appropriately and including covariates to account for differences in 
genetic admixture, we determined the p-value for each SNP’s association with every 
clinical phenotype. In a logistic regression, the p-value gives the probability that the 
frequency of the minor allele of a SNP is the same in the people with a sub-phenotype, 
such as the people with anti-dsDNA, and the people without the sub-phenotype. The 
logistic regression analysis was first done on subjects of European ancestry, then on 
Asians, African Americans, and Hispanics. The accepted alpha error rate is 0.05, but 
because we performed many independent tests, a multiple testing correction had to be 
used. This correction takes into account the number of SNPs compared, as well as the 
number of clinical phenotypes analyzed. Using this correction, a significant p-value was 
determined to be 1.6x10
-5
.  
 In European Americans, the logistic analysis identified three sub-phenotypes that 
were significantly associated with SNPs in and around the IRF5/TNPO3 genes (p-value 
less than 1.6x10
-5
). These were the age of onset of lupus (how old a person is when they 
develop lupus), the presence of anti-Ro autoantibodies, and the presence of anti-dsDNA 
autoantibodies. Anti-Ro autoantibodies target the Ro ribonucleoprotein, which is 
normally found in the nucleolus of the cell, while anti-dsDNA autoantibodies target 
double stranded DNA (dsDNA). These autoantibodies are not normally formed in 
absence of an autoimmune response. In African Americans and Asian Americans, there 
was a statistically significant association to age of onset, but not to the other symptoms.  
 A conditional analysis (see Chapter 3) was conducted for each of the three 
statistically associated symptoms, similar to the conditional analyses that demonstrated 
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the two independent SNP groups that were associated with SLE development. This 
analysis revealed an association with specific SNPs in the IRF5/TNPO3 area. For age of 
onset of lupus, there was a statistically significant association with the SNP rs12534421. 
Nearly all phenotype association was removed when the impact of this SNP and all 
associated variants were removed in the analysis. When the symptom association with the 
next significant SNP, rs4728142, was removed, no SNP association with the age of onset 
remained. This demonstrated that all associated SNPs were linked to SNPs rs4728142 
and rs12534421.  
 For the presence of anti-Ro and anti-dsDNA autoantibodies, the conditional 
analysis showed association to rs4728142, the primary variant associated with SNPs in 
the promoter region of IRF5. After conditioning on (removing the impact of all SNPs 
associated with) rs4728142, there was still association with a few SNPs spanning IRF5 
and TNPO3 genes (those variants in linkage disequilibrium with rs12534421), but most 
of the association was with genetic variants in the promoter.  
 The fact that different groups of SNPs in the IRF5/TNPO3 region were 
statistically associated with the development of different lupus symptoms provides  
support to the theory that there are two independent groups of variants in this region, and 
that they play separate roles in the development of SLE. This will allow future studies to 
specifically focus on the IRF5/TNPO3 region. My results also support previous studies of 
these two SNP groups and could refine the study of the biological processes that are 
impacted by these variants by directing the focus towards each of the SNP groups 
separately.  
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 Additionally, our work to identify variants associated with the development of 
specific symptoms in people with lupus has immediate therapeutic implications. Lupus is 
a relatively rare disease, and doctors are unlikely to prophylactically treat healthy people 
who are genetically predisposed to lupus. Once people have lupus, however, there are 
different therapeutic options that vary in their aggressiveness. This study may also 
contribute to the type of personalized medicine that is the future of health care. 
 At the end of the summer, I was able to present my research at the University of 
Cincinnati’s Undergraduate Research Symposium, where I earned an honorable mention. 
In January 2013, I returned to the Rheumatology Department to complete additional data 
analyses, instruct a new graduate student in programming with PLINK, and assemble 
cohesive, straightforward instructions for future sub-phenotypic, conditional analysis 
research in this field.  
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CHAPTER 2 
 
 
INTRODUCTION 
 
 
Systemic Lupus Erythematosus (SLE or lupus) is an autoimmune disorder 
affecting every organ in the body [1]. Patients must display four of eleven clinical 
findings for official diagnosis according to the American College of Rheumatology [5, 6]. 
One in every 5,000 people will be diagnosed with lupus, with 90% of them being female 
(Figure 3). African Americans and Asians are three to four times more likely to develop 
lupus than persons of European descent, and African American, Asian, and Hispanic 
ancestries have a greater mortality rate from this disease [2-4]. Without sophisticated 
medical care, SLE has a 50% mortality rate [7].  
Genetic factors play a significant role in the etiology of lupus [8]. Previous studies 
have demonstrated the effect of genetic variants on the development of specific 
symptoms in lupus patients [9-15]. The Interferon Regulatory Factor 5 (IRF5) functions 
within the interferon inflammatory pathway and is critical for lupus pathogenesis [15-19]. 
Single nucleotide polymorphisms (SNPs) within the IRF5 and the nearby Transportin 3 
(TNPO3) genes are highly associated with the etiology of lupus, but genetic variant 
associations with specific clinical phenotypes of SLE have not yet been identified [20-
36].  Prior studies indicate that genetic association occurs through two independent 
groups of linked SNPs at the IRF5/TNPO3 locus [37]. Variants in the promoter region are 
present across ancestries and are accounted for by the rs4728142 SNP, while variants 
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spanning the IRF5/TNPO3 region are present only in populations with European 
admixture and are strongly linked to the SNP rs12534421.  
The purpose of this study was to determine if either of these two genetic effects at 
the IRF5/TNPO3 locus are statistically associated with specific clinical phenotypes in 
patients with lupus. The study also investigated how sub-phenotypic associations in 
IRF5/TNPO3 vary across different ancestries. Our data indicate that the two effects are 
independently associated with three different lupus phenotypes in European Americans, 
but only one effect is evident in African Americans, Asians, and Hispanics.  
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CHAPTER 3 
 
 
MATERIALS AND METHODS 
 
 
Subjects 
The study included 3,926 European, 1,257 Asian, 1,287 Hispanic, and 1,524 
African-American SLE patients, all of whom met the American College of 
Rheumatology (ACR) SLE classification criteria. Phenotypic data and patient DNA were 
collected with informed consent and IRB approval by several institutions around the 
globe. Thirty-one clinical phenotypes were analyzed, each of which fall into one of the 
following categories: age of onset of lupus, presence of certain autoantibodies, false 
positive syphilis test, discoid rash, malar rash, renal disorders, neurologic disorders, oral 
ulcers, photosensitivity, and hematologic disorders.  
Genotyping 
Patient DNA was genotyped on an iSCAN array genotyping instrument using the 
Illumina custom bead system. One hundred and one lupus susceptibility loci in the 
IRF5/TNPO3 region were identified for each patient. SNPs were located in a 437,000 
base pair region, ranging from 167 kbp upstream of IRF5 to 61 kbp downstream of 
TNPO3. Admixture markers, which indicate ancestral origins, were genotyped and 
analyzed for each sample to determine admixture from five ancestries: European 
American, African American, Asian and Asian American, and Hispanic American [38-
41]. 
 12 
 
Statistical analysis 
Two main types of analyses were used in this study. The first was a logistic 
regression analysis of all SLE symptoms. This analysis compared the presence of 
different risk alleles with the presence of each symptom, identifying any association. It 
then determined a p-value, which was the probability that the observed association could 
randomly occur. The logistic regression served to identify lupus symptoms for which 
SNPs in the IRF5/TNPO3 region were significantly associated.  
A sub-phenotypic logistic regression analysis was conducted using PLINK 
version 1.07, a program designed to analyze SNPs and their associations with phenotypic 
data. Admixture covariates were included in the program to account for variances in 
ancestry and each ancestry was individually assessed. Using the most stringent 
Bonferroni multiple testing correction (p = 0.05/(number of variants x number of 
phenotypes) = 0.05/(101 x 31)), a significant p-value was determined to be 1.6x10
-5
. 
Additional label-swapping iterative permutation testing showed that empirically 
significant p-values for each SNP are actually closer to 10
-4
. This test swaps the symptom 
affectedness status (from unaffected to affected, or vice versa) for a random selection of 
patients, and checks to see if SNP association still exists. It repeats this process several 
thousand times, and uses the results to calculate the probability of SNP association 
randomly occurring. The sub phenotypic logistic regression analysis of lupus patients 
identified three symptoms with significant p-values. The additional permutation testing 
confirmed that no other symptoms were significantly associated.  
Aside from the logistic analysis, the second main test used in this study is a 
conditional analysis. This test determines how many SNPs are actually associated with a 
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specific symptom. For a single symptom, this analysis removes the most associated SNP, 
and all of the SNPs that are linked with it. It is then possible to see if any SNPs not 
connected with the first SNP are associated with the symptom. For a step-wise 
conditional analysis, the symptom is “conditioned” (the association is removed) for the 
most associated SNP, followed by the next remaining SNP, then both SNPs 
simultaneously, in a series of steps that result in the removal of all significant SNP 
association. The conditional analysis shows the top two most associated SNPs that are not 
linked to each other. It could be used to identify more associations, but after the 
association of the top two are removed, very little SNP association remains. 
A conditional analysis was conducted in PLINK v 1.07 to determine which SNPs 
were statistically associated with these three phenotypes [42]. Phenotypic associations 
were conditioned step-wise using the SNPs that account for the two linked SNP groups in 
the IRF5/TNPO3 area: the SNP rs4728142, which is associated with genetic variants in 
the promoter region of IRF5, and the SNP rs12534421, which is associated with variants 
spanning IRF5 and TNPO3. In cases where the SNPs most associated with lupus 
development differed from those most associated with the specific symptoms, the SNPs 
most associated with the symptoms were used for the conditional analysis. This was the 
case for anti-Ro and anti-dsDNA. In these cases, conditional analyses were conducted 
with the two main SNPs for lupus development in addition to the two most associated 
symptomatic SNPs. 
 14 
 
CHAPTER 4 
 
 
RESULTS 
 
 
The three clinical phenotypes that demonstrate statistically significant association 
with variants in IRF5 and TNPO3 are: age of onset of lupus (p valueEU = 2.44x10
-16
, Odds 
Ratio = 0.67*), the presence of anti-Ro antibodies (p valueEU = 2.09x10
-7
, Odds Ratio = 
0.67), and the presence of anti-dsDNA antibodies (p valueEU = 4.15x10
-7
, Odds Ratio = 
0.75). Of the three phenotypes, age of onset of lupus was the only one that was 
significantly associated across all three ethnicities (European American, African 
American, and Asian). Testing revealed no genetic association with any symptom in 
Hispanics. The presence of anti-Ro antibodies was associated with variants in Europeans 
only, and the presence of anti-dsDNA antibodies displayed SNP association in Europeans 
and African Americans. In Europeans, the SNP rs3778752 had the lowest p value for the 
presence of both anti-Ro and anti-dsDNA antibodies. For age of onset of lupus, the SNP 
rs4728142 was most significantly associated in both African Americans and Asians, but 
not in Europeans.  
For all three phenotypes, genetic variant association was no longer significant 
when the phenotypic association resulting from the two most associated SNPs was 
removed. With age of onset, the group of SNPs spanning IRF5/TNPO3 (closely linked to 
the SNP rs12534421) and the group of genetic variants in the promoter region of IRF5 
(closely linked with the SNP rs4728142) have significant association in Europeans, with 
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variants linked to rs12534421 having the lowest p values (Figure 4). This is 
shown by the sharp decline in statistical significance (-log p value) when each SNP is 
conditioned separately. For the presence of anti-Ro and anti-dsDNA antibodies, the 
promoter group (rs4728142 and associated SNPs) had the greatest effect (Figures 5-6). 
Although rs4728142 and rs12534421 are most closely associated with the 
development of lupus and the two genetic effects in the IRF5/TNPO3 region, rs3778752 
was most closely linked to the presence of anti-Ro and anti-dsDNA antibodies. The 
rs3778752 risk allele is a part of the SNP group in the promoter region of IRF5. In 
association studies, rs3778752 had lower p-values than rs4728142 in both anti-dsDNA 
(prs37778752 = 4.154 x 10
-7
, prs4728142 = 5.85 x 10
-6
) and anti-Ro (prs37778752 = 2.09*10
-7
, 
prs4728142 = 9.37 x 10
-7
). We identified chromosomes in European Americans in which the 
two SNPs segregate (n = 1992) and the subjects have either anti-dsDNA or anti-Ro 
antibodies (n = 624). Our results show that subjects with anti-Ro or anti-dsDNA 
antibodies are 133% more likely to have the rs3778752 risk allele than the rs4728142 risk 
allele.   
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Age of Onset 
 
 
 
 
Figure 4. Conditional analysis of age-of-onset phenotype. The horizontal bars show the position on 
chromosome 7 of IRF5 and TNPO3.The most associated SNPs are identified in A, B, and C. Graph A 
shows the statistical significance (-log10[p-value]) of each SNP in the IRF5/TNPO3 region. For graphs B 
and C, we removed each of the top two most associated SNPs. Graph D removes the association of both 
SNPs. From this, we conclude that rs12534421 (the second group of linked SNPs) is responsible for most 
of the statistical association between genetic variants and the age of onset of lupus. When the contribution 
of both SNPs is removed, no association remains p<0.01 (D). 
A 
D 
C B 
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Anti-Ro 
  
 
 
 
Figure 5. Conditional analysis of the presence of anti-Ro antibodies. Graph A shows the statistical 
significance (-log10[p-value]) of the association of each SNP in the IRF5/TNPO3 region with the presence 
of anti-Ro antibodies. For graphs B and C, we removed the association of the two most significant SNPs 
(which did not include rs4728142 or rs12534421) separately. The bottom graph removes the association of 
both SNPs. From this, we can conclude that rs3778752 (the first SNP group) is responsible for most of the 
statistical association of genetic variants with the presence of anti-Ro antibodies.  
 
D 
C B 
A 
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Anti-dsDNA 
 
 
 
 
Figure 6. Conditional analysis of the presence of anti-dsDNA antibodies. Graph A shows the significance 
(-log10[p-value]) of the association of each SNP in the IRF5/TNPO3 region with the presence of anti-
dsDNA antibodies. For graphs B and C, we conditioned separately on the two most closely associated 
SNPs. Graph D adjusts for the association of both SNPs. From this, we can conclude that rs3778752 (the 
first SNP group) is responsible for most of the statistical association of genetic variants with the presence of 
anti-dsDNA antibodies.  
 
D 
C B 
A 
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CHAPTER 5 
 
 
DISCUSSION 
 
 
Genetic Variant Association 
Defined connections between genetic variants and lupus sub-phenotypes may 
enable increased understanding of the etiology of lupus. These connections may also 
allow clinical practitioners to predict a patient’s risk of developing specific symptoms. In 
this study, variants in IRF5 and TNPO3 that are already known to be statistically 
associated with the development of lupus were shown to be connected with specific sub 
phenotypes including age of onset of lupus and the production of anti-Ro or anti-dsDNA 
antibodies.  Association was found largely in European American subjects but was also 
present in African Americans and Asians to a lesser degree.  
 
Two Independent Genetic Effects 
Although the two groups of linked SNPs in IRF5 and TNPO3 are highly 
associated with the development of lupus, genetic variants in the promoter of IRF5 
(linked to the SNP rs4728142) and genetic variants spanning IRF5 and TNPO3 (linked to 
the SNP rs12534421) are independently associated with specific symptoms of lupus. This 
supports the hypothesis that these are indeed two separate SNP groups which play 
different roles in SLE. The group spanning IRF5/TNPO3 only displays significance in 
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European Americans, while the promoter group plays a role in all ethnicities. This 
could signify that SNPs in the promoter of IRF5 are part of an ancient set of variants, 
while the group of associated SNPs spanning IRF5 and TNPO3 are the result of more 
recent variation.  
 
SNP Association Differences 
The rs3778752 risk allele shows 133% more association with the presence of anti-
Ro and anti-dsDNA antibodies than the rs4728142 risk allele. Our results suggest that 
although rs4728142 is one of the most significant indicators of lupus risk, rs3778752 
seems to be far more effective in predicting the production of anti-Ro and anti-dsDNA in 
the body. 
 
Conclusion 
In conclusion, our study shows that genetic variants in the IRF5/TNPO3 genes are 
associated with specific clinical phenotypes of lupus. The two independent SNP groups 
in this region function separately in the different symptoms as well as in the different 
ethnicities. Our data support prior findings that the two etiological effects are associated 
with different ancestries, and indicate that genetic variant groups in IRF5/TNPO3 
function differently in the development of certain lupus phenotypes.  
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